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Edited by Michael R. BubbAbstract Inhibition of double-stranded RNA-dependent protein
kinase (PKR) represents an interesting strategy for neuroprotec-
tion. However, inhibiting this kinase which triggers the apoptotic
process could favour in counterpart cell proliferation and tumor-
igenesis. Here, we use an in vivo model of 7-day-old rat display-
ing a high activation of brain PKR to investigate the eﬀects of a
new PKR inhibitor identiﬁed as an oxindole/imidazole derivative
(C16). We show for the ﬁrst time that acute systemic injection of
C16 speciﬁcally inhibits the apoptotic PKR/eIF2a signaling
pathway without stimulating the proliferative mTOR/p70S6K
signaling mechanism.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Neuroprotection1. Introduction
Initiation of protein synthesis is regulated by kinase-
dependent phosphorylation reactions. Double-stranded
RNA-dependent protein kinase (PKR) and mammalian target
of rapamycin (mTOR) are two important kinases controlling
this initiation step [1,2]. mTOR, which can phosphorylate
downstream targets such as the ribosomal S6 kinases
(p70S6K) [3,4], positively regulates protein translation and is
involved in cell growth and proliferation (for review, see
[5,6]). At the opposite, PKR is a serine/threonine stress kinase
which is activated by several agents including virus, interferon
alpha, and calcium [1,7] leading to its autophosphorylation.
Once activated, PKR can phosphorylate the eukaryotic initia-
tion factor 2a (eIF2a) on serine 51 which in turn blocks the ini-
tiation of protein synthesis [8]. Activated PKR has beenAbbreviations: PKR, double-stranded RNA-dependent protein kinase;
mTOR, mammalian target of rapamycin; p70S6K, 70-kDa S6 kinase;
eIF2a, eukaryotic initiation factor 2a; C16, oxindole/imidazole com-
pound; AD, Alzheimer’s disease; Ab, b-amyloid peptide; APP,
amyloid precursor protein; PS1, presenilin 1; KI, knock in; 2-AP, 2-
aminopurine; PRI peptide, cell-permeable peptide containing the
RBDI of PKR; BBB, blood brain barrier
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doi:10.1016/j.febslet.2007.08.022involved in the pathogenesis of neurodegenerative disorders
such as Huntington, Parkinson and Alzheimer’s diseases [8–
11] in which a clear neuronal loss is observed in speciﬁc brain
regions. Thus, pharmacological inhibition of PKR seems to
represent an interesting strategy. Indeed, several molecules
have been used to inhibit PKR. 2-Aminopurine (2-AP) was
shown to inhibit the autophosphorylation of PKR and the
subsequent phosphorylation of eIF2a at millimolar concentra-
tions both in vitro and in vivo [12]. Unfortunately, 2-AP inhib-
its several kinases at these relatively high concentrations [13].
A cell-permeable peptide (PRI) containing a conserved
dsRNA binding motif found in PKR was reported to inhibit
activation of PKR and phosphorylation of its substrate,
enhancing cell proliferation [14]. We previously conﬁrmed
the neuroprotective eﬀect of cell-permeable peptide containing
the RBDI of PKR (PRI peptide) in b-amyloid peptide (Ab) –
induced apoptosis in SH-SY5Y cells [11]. Recently, a new
ATP-binding site directed PKR’s inhibitor was identiﬁed
[15]. This oxindole/imidazole compound (C16) is a small mol-
ecule able to inhibit the autophosphorylation of PKR and to
rescue the translation blockade induced by PKR. In a recent
work, we revealed that C16 prevent not only PKR phosphor-
ylation but also the activation of caspase 3 induced by Ab in
SH-SY5Y cells [11]. In addition, a recent study has reported
the protective eﬀect of C16 on the neuronal cell death induced
by endoplasmic reticulum-stress in SH-SY5Y cells [16]. How-
ever, inhibiting the PKR/eIF2a signaling pathway which is in-
volved in the triggering of apoptotic process could activate in
counterpart pathways including kinases like mTOR and lead-
ing to cell proliferation and tumorigenesis.
The goal of the present study is to propose an animal model
which displays a high PKR activity in order to further study
the eﬀects of potential PKR’s inhibitors in vivo. For this pur-
pose, we analyzed the brain levels of activated and total PKR
in rat at various ages. Then, we evaluate the eﬀects of systemic
injections of C16 on both the PKR/eIF2a and mTOR/p70S6k
signaling pathways in the brains of 7-day-old rats.2. Materials and methods
2.1. Chemicals
All chemicals were obtained from VWR International (Strasbourg,
France) or Sigma (St. Quentin Fallavier, France). C16 compound
was purchased from Calbiochem VWR International (Strasbourg,
France). Most of primary antibodies and secondary anti-rabbit IgGblished by Elsevier B.V. All rights reserved.
4474 S. Ingrand et al. / FEBS Letters 581 (2007) 4473–4478antibody conjugated with horseradish peroxidase were purchased from
Cell Signaling (Ozyme distributor, St. Quentin Yvelines, France)
excepted for anti-PERK which was from Santa Cruz (Tebu-Bio dis-
tributor, Le Perray en Yvelines, France), anti-b-actin antibody from
Sigma and peroxidase-conjugated anti-mouse IgG from Amersham
Biosciences (Orsay, France).
2.2. Animal treatment
All animal care and procedures were carried out in accordance with
local guidelines. All eﬀorts were made to minimize animal suﬀering and
discomfort. To determine the highest activation of PKR, Sprague-
Dawley rats of 7-day, 1, 2, 4, 6, 9 and 12-month-old were used.
Seven-day-old rats were intraperitoneally (ip) injected with a single
dose (200 lL) of C16 at the concentrations of 0.335, 3.35, 33.5 or
167.5 lg/kg of body weight. Animal well-being is controlled by keeping
a close eye on behavioural aspects (fear, aggressiveness, suﬀering, and
pain). Injection of C16 at 335 lg/kg of body weight was shown to be
lethal. Stocked solutions of C16 were prepared in DMSO (ﬁnal con-
centration: 0.5%). Control rat pups were injected with 0.5% DMSO.
Animals were decapited at 3 h, 6 h and 9 h post-treatment after isoﬂu-
rane anaesthesia.7-D
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Fig. 1. Age-related expression of active PKR. Representative immunoblot a
the total form of PKR in rat brain. (C) Ratio p-PKR/PKR calculated fro
means ± S.E.M. of 3–4 rats of each age. *P < 0.05; **P < 0.01 compared to2.3. Preparation of rat brain samples
Cortex were homogenized in 20 volumes of lysis buﬀer as previously
described [11]. Lysates were sonicated and centrifuged at 15000 · g for
15 min at 4 C. The resulting supernatants were collected for BioRad
protein assay and Western blot analysis as described below.
2.4. Immunoblottings
Proteins (30 lg) were separated on a 7% or 10% Tris–glycine poly-
acrylamide gels and transferred to polyvinylidene diﬂuoride (PVDF)
membranes (Immobilon-P, Millipore, Bedford, MA, USA) as previ-
ously described [17,18]. The primary polyclonal antibodies used were
rabbit anti-phosphorylated PKR at threonine 446 (1:500 dilution), rab-
bit anti-PKR (1:1000), rabbit anti-phosphorylated eIF2a at serine 51
(1:250), rabbit anti-eIF2a (1:1000), rabbit anti-phosphorylated PERK
at threonine 980 (1:500), rabbit anti-PERK (1:500), rabbit anti-phos-
phorylated mTOR at serine 2448 (1:250), rabbit anti-mTOR (1:250),
rabbit anti-phosphorylated 70-kDa S6 kinase (p70S6K) at threonine
389 (1:1000), rabbit anti-p70S6K (1:1000). Membranes were then incu-
bated with the secondary antibody:peroxidase-conjugated anti-rabbit
IgG (1:1000). Membranes were developed with the chemiluminescence
ECL plus Western blotting system (Amersham Biosciences), followedh-o
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S. Ingrand et al. / FEBS Letters 581 (2007) 4473–4478 4475by apposition of the membrane to high performance chemilumines-
cence ﬁlms (Hyperﬁlm ECL, Amersham Biosciences). Band intensi-
ties were analyzed by densitometry with a gel documentation system
(Biorad, France). The immunoreactivity for b-actin (1:1000) was con-
trolled to exclude that various amounts of material were loaded. Acti-
vation of the proteins was determined as the ratio between the
phosphorylated and the total form of the corresponding kinases.
2.5. Statistical analyses
Results were expressed as means ± S.E.M. values and were statisti-
cally analyzed using the one-way analysis of variance (ANOVA) test
followed by Bonferroni’s test. Results were considered signiﬁcantly dif-
ferent when P < 0.05.3. Results and discussion
Previous studies have underlined the role of PKR/eIF2a sig-
naling pathway in neurodegenerative disease such as Alzhei-
mer’s disease (AD). We previously showed that PKR was
activated and eIF2a phosphorylation was signiﬁcantly in-
creased in Ab-induced apoptosis in neuroblastoma cells and
neuronal cultures [7,19] as well as in the brains of APPSL/
PS1 knock in (APPSL/PS1 KI) mutant transgenic mice [11].
Thus, the inhibition of PKR could represent an interesting
strategy to downregulate eIF2a phosphorylation which is in
part responsible for the translation block and then to attenuate
neuronal cell apoptosis. For this purpose, we need an in vivo
model in which PKR is highly activated. In the present study,phospho-PKRThr446
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Fig. 2. Eﬀect of C16 on the PKR/eIF2a signaling pathway. Representative im
and (C) the phosphorylated (Ser51) and total forms of eIF2a in rat brain.
densitometric analyses of blots. Results are expressed as the means ± S.E.
***P < 0.001 compared to control.the expression of active PKR was explored in the brain of rats
aged from 7-day-old to 12-month-old. As shown in Fig. 1A,B,
the phosphorylated form of PKR is slightly higher whereas the
total form of PKR is really lower in the brain of 7-day-old rats
compared with all other ages investigated. Consequently, the
ratio between phospho-PKR and total PKR (p-PKR/PKR)
which accounts for the activation of the protein is the highest
in the brain of 7-day-old rats (Fig. 1C). These data suggest that
PKR is very early activated in rat brain and then rapidly and
signiﬁcantly decrease to reach about one half of the 7-day-old
value as soon as 1-month of age. Considering the link between
PKR activation and apoptosis, our results are in agreement
with studies that reported enhanced programmed cell death
in the cerebral cortex of the rat at the embryonic stage and
during the ﬁrst 10 days of postnatal life with a peak at the
end of the ﬁrst week [20,21]. Therefore, rat pups constitute
an interesting animal model to test the eﬀectiveness of various
PKR inhibitors in vivo.
Recently, a potent and selective small molecule described to
be an oxindole/imidazole derivative was reported to be an
eﬀective inhibitor of RNA-induced PKR autophosphorylation
and to rescue PKR-dependent translation block in vitro [15].
In order to evaluate the in vivo inhibitory eﬀects of this newly
PKR inhibitor C16, 7-day-old rats were ip injected with
increasing concentrations of C16 and brains were dissected
3 h post treatment. Because of the lack of pharmacokinetics
data for this new compound C16, the 3 h time point was ini-167
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Fig. 3. Eﬀect of C16 on the mTOR/p70S6K signaling pathway. Representative immunoblots of (A) the phosphorylated (Ser2448) and total forms of
mTOR and (C) the phosphorylated (Thr389) and total forms of p70S6K in rat brain. (B) Ratio p-mTOR/mTOR, (D) Ratio p-p70S6K/p70S6K
calculated from the densitometric analyses of blots. Results are expressed as the means ± S.E.M. of 6 rats for each experimental condition. *P < 0.05;
**P < 0.01; ***P < 0.001 compared to control.
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immunoblots of (A) the phosphorylated (Thr980) and total forms of
PERK. (B) Ratio p-PERK/PERK calculated from the densitometric
analyses of blots. Results are expressed as the means ± S.E.M. of 6 rats
for each experimental condition.
S. Ingrand et al. / FEBS Letters 581 (2007) 4473–4478 4477tially chosen to allow C16 to reach the brain after an ip injec-
tion. Fig. 2A,C show typical immunoblots of PKR (phosphor-
ylated and total forms) and its downstream target eIF2a
(phosphorylated and total forms). The densitometric analysis
of blots reveals a signiﬁcant dose dependent decrease of the ra-
tio p-PKRThr446/PKR which reaches 46%, 52% and 58% of the
control value after C16 injection of 3.35, 33.5 and 167.5 lg/kg
of body weight, respectively (Fig. 2B). This inactivation is
associated with a signiﬁcant reduction of the ratio p-eIF2a/
eIF2a estimated at 45%, 49% and 51.5% of the control value
after C16 injection of 3.35, 33.5 and 167.5 lg/kg, respectively
(Fig. 2D). Taken together, these results demonstrate ﬁrstly
the capacity of C16 to cross the blood brain barrier (BBB) in
our model. However, the BBB is more permeable in new born
rats and therefore it may be diﬃcult to extrapolate these results
to adult animals [22]. Moreover, these ﬁndings clearly suggest
that an in vivo acute treatment with C16 is able to block the
proapoptotic PKR/eIF2a signaling pathway and underscore
the fact that in vivo PKR inhibition is a feasible approach to
modulate neurodegeneration. In addition, as the results show
(Fig. 2B,D), PKR inhibition is already signiﬁcant with a dose
as low as 3.35 lg/kg, i.e. 1 lM. Higher doses lead only to a
slight additional decrease.
However, as mentioned above, inhibiting the PKR/eIF2a
pathway could activate in counterpart pathways leading to cell
proliferation and tumorigenesis. Indeed, previous studies have
reported that expression of a catalytically inactive mutant of
PKR in NIH-3T3 cells led to their transformation capable of
generating tumors in nude mice [23,24]. Conversely, mice
genetically ablated for functional PKR showed no apparent in-
crease in their susceptibility to develop tumors [25,26] indicat-
ing that regulation of these mechanisms is a complex process
which remains to be elucidated. It is well known that mTOR
is an oncogenic protein involved in the control of cellular
growth and proliferation. So, in our experiments, we also
investigate the C16 eﬀects on the mTOR/p70S6K signaling
pathway in vivo. As depicted in Fig. 3, no modiﬁcation is ob-
served in the phosphorylated and total forms of mTOR
(Fig. 3A) and p70S6K (Fig. 3C) whatever the C16 concentra-
tion used compared with control. Consequently, there is no
activation of mTOR (Fig. 3B) and p70S6K (Fig. 3D) when
7-day-old rats were treated with C16 for 3 h. In addition, 7-
day-old rats were treated for 6 h and 9 h with the lowest
(3.35 lg/kg) and the highest (167.5 lg/kg) doses of C16 which
already displayed a signiﬁcant PKR inhibition. In these condi-
tions, the phosphorylated and total forms of mTOR remain
unchanged (Fig. 4A), indicating that no delayed activated
mTOR response develops as a consequence of PKR inhibition
(Fig. 4B). However, it should be noted that no more inhibition
of PKR is observed after these long periods of treatment (Figs.
4C,D). The eﬀectiveness of C16 seems to be time limited.
Because of the lack of pharmacokinetics data and in particular
the half life of the compound, we can speculate that C16 is
degraded after several hours of treatment.
To verify the speciﬁty of C16 towards PKR in vivo, we
examined PERK, another protein kinase that is also able to
phosphorylate eIF2a, for inhibition by C16. The results de-
picted in Fig. 5 indicate no modiﬁcation in the phosphorylated
and total form of PERK (Fig. 5A) whatever the C16 concen-
tration used compared with control. Consequently, there is
no inhibition of PERK by C16 (Fig. 5B).In this study, we propose a 7-day-old rat model which phys-
iologically displays a high activation of brain PKR. This could
provide a useful in vivo model for the screening of PKR inhib-
itors in order to determine their physical and behavioural tol-
erance together with their ability to cross the BBB. This could
also allow to deﬁne the dose (concentrations and period of
time) and to select the most eﬃcient PKR inhibitors before
testing promising molecules in a more expensive model such
as transgenic mice. To our knowledge, this is the ﬁrst study
underlying the in vivo C16-dependent speciﬁc inhibitory eﬀect
of the apoptotic PKR/eIF2a signaling pathway without trig-
gering the proliferative mTOR/p70S6K signaling mechanism.
In the context of neuropathological diseases, such as AD, fur-
ther studies will have to be performed in order to conﬁrm the
in vivo neuroprotective role of C16.
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